A summary of the ADVANCE Trial.
Heller
Simon R
SR
Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield Medical School, Sheffield, U.K. s.heller@sheffield.ac.uk
D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D003925:Diabetic Angiopathies / Q000453:epidemiology / Q000517:prevention & control; D003930:Diabetic Retinopathy / Q000453:epidemiology; D018450:Disease Progression; D006442:Glycated Hemoglobin / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use*; D050177:Overweight / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D014652:Vascular Diseases / Q000517:prevention & control
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D008687:Metformin; D013453:Sulfonylurea Compounds